Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A self-assembling ferritin nanoparticle-based trivalent vaccine of gB/gE/gH elicits potent immune responses against varicella-zoster virus.

International journal of biological macromolecules·2026
Same author

High-performance mid-wave infrared metasurface for broadband linear-to-circular polarization transformation.

Optics express·2025
Same author

The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation.

Journal of virology·2025
Same author

The RNA-binding protein RBM39 scaffolds an m⁶A-dependent RNA decay complex that destabilizes Tat transcripts and restricts HIV-1 reactivation.

PLoS biology·2025
Same author

Particle size-dependent neurotoxicity of microplastics in zebrafish (Danio rerio): Spatially resolved lipidomics links metabolic dysregulation to neurological disorders.

Journal of hazardous materials·2025
Same author

Development of an Assay Evaluating the Inducible HIV-1 Latent Reservoir Based on Reverse Transcription Droplet Digital PCR for Unspliced/Intact Viral RNA.

Journal of medical virology·2025
Same journal

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Cell reports. Medicine·2026
Same journal

Microglial IL-27 modulates depression-like behaviors induced by postnatal immune activation.

Cell reports. Medicine·2026
Same journal

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.

Cell reports. Medicine·2026
Same journal

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cells.

Cell reports. Medicine·2026
Same journal

Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.

Cell reports. Medicine·2026
Same journal

Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.

Cell reports. Medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.1K

Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.

Qiannan Fang1, Xinyu Lu2, Yuanqiang Zhu3

  • 1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China; Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China.

Cell Reports. Medicine
|June 19, 2024
PubMed
Summary
This summary is machine-generated.

A novel nanoparticle vaccine targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) effectively lowers cholesterol and reduces atherosclerosis. This innovative vaccine shows promise for treating hypercholesterolemia and related cardiovascular diseases.

Keywords:
LDLRPCSK9T follicular help cellshypercholesterolemiananoparticle vaccine

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Related Experiment Videos

Last Updated: Jun 23, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.1K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Nanomedicine

Background:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in regulating low-density lipoprotein receptor (LDLR) degradation, leading to elevated LDL cholesterol.
  • Elevated LDL cholesterol is a major risk factor for atherosclerosis and cardiovascular disease.
  • PCSK9 has emerged as a significant therapeutic target for managing hypercholesterolemia.

Purpose of the Study:

  • To develop and evaluate a novel nanoparticle (NP) vaccine targeting PCSK9.
  • To assess the vaccine's efficacy in reducing serum lipids and mitigating atherosclerosis in preclinical models.
  • To elucidate the immunological and cellular mechanisms underlying the vaccine's therapeutic effects.

Main Methods:

  • Conjugation of the catalytic domain of PCSK9 to self-assembled 24-mer ferritin NPs to create the PCSK9 NP vaccine.
  • Evaluation of the vaccine in high-fat diet-induced and AAV-hPCSK9-induced hypercholesterolemia mouse models.
  • Assessment of atherosclerotic plaque burden and macrophage infiltration in a relevant mouse model.
  • Investigation of the roles of T follicular helper cells and LDLR in vaccine efficacy.

Main Results:

  • The PCSK9 NP vaccine successfully induced interfering antibodies against PCSK9.
  • Significant reductions in serum lipid levels were observed in both hypercholesterolemia models.
  • The vaccine markedly decreased atherosclerotic plaque areas and macrophage infiltration in the aorta.
  • Vaccine efficacy was demonstrated to be dependent on T follicular help cells and LDLR.

Conclusions:

  • The developed PCSK9 NP vaccine is a promising immunotherapeutic strategy for hypercholesterolemia.
  • This novel vaccine effectively reduces atherosclerosis progression in preclinical models.
  • The findings support the potential of PCSK9 NP vaccines as a novel treatment for cardiovascular diseases.